We experienced an insulin-requiring NIDDM patient whose glucose tolerance deteriorated 4 days after the initiation of interferon-α(6MU/day) therapy for type C chronic active hepatitis.
The patient, a 62-year-old man, was diagnosed as having NIDDM in 1976. He was admitted to our hospital in November of 1988 and thereafter maintained good control with oral hypoglycemic agents (OHA). The diagnosis of type C chronic hepatitis was made in September of 1992. The levels of postprandial plasma glucose and glycosylated hemoglobin (HbA
1c) increased following the administration of interferon-α(INF). After the therapeutic modality of diabetes mellitus was changed from OHA to preprandial injection of the short-acting insulin (three times per day), the levels of HbA
1c and postprandial plasma glucose started to decrease and strict glycemic control was attained. It became possible to revert to OHA after the cessation of INF therapy.
In this case, there were no changes in the insulinogenic index on 75 gram oral glucose tolerance test (OGTT) or fasting counterregulatory hormones during or after INF therapy, while glucose tolerance was aggravated on OGTT and euglycemic hyperinsulinemic clamp study (95mg/d
l, 200μU/m
l), using an artificial endocrine pancreas, revealed that the glucose disposal rate in peripheral tissue improved from 6.9mg/kg/min to 8.2mg/kg/min after the discontinuation of INF therapy.
These observations indicate that the deterioration of glucose tolerance in this case was probably due to increased insulin resistance induced by the administration of INF.
View full abstract